SELECT Trial Results: How Semaglutide Cuts Cardiovascular Risk by 20%

A 52-year-old woman. LDL creeping up, blood pressure borderline, an echocardiogram this year noting early changes her doctor called “established cardiovascular disease.” Four months ago she started a GLP-1 for weight management. Now her physician is telling her something unexpected: the same medication may also be reducing her cardiovascular risk by 20% — and the connection between GLP-1 heart disease outcomes and her treatment plan is no longer just emerging research. It is an FDA-approved indication backed by one of the largest cardiovascular trials ever conducted on a weight-loss medication. This isn’t a side benefit. It’s a documented FDA-approved indication based on one of the largest clinical trials ever run on a weight-loss medication.

This is post #4 in our series, The GLP-1 Benefits Nobody’s Talking About — See the Full Guide →

What the SELECT Trial Actually Tested

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with BMI of 27 or above and established cardiovascular disease — prior heart attack, stroke, or peripheral arterial disease — none of whom had diabetes. Participants were randomized to semaglutide 2.4mg weekly or placebo and followed for over three years. The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — the standard MACE endpoint in cardiology trials. Semaglutide reduced MACE by 20% versus placebo (6.5% vs. 8.0% event rates), a clinically meaningful result in a high-risk population.

How a Weight Loss Drug Became a Cardiovascular Drug

The obvious question: isn’t this just weight loss? Patients on semaglutide lost roughly 9-10% of body weight vs. about 1% on placebo. But cardiovascular benefit appeared earlier than the weight-loss curve would predict — separation in outcomes was detectable within the first few months, before significant weight had been lost. This suggests at least some of the effect is independent of weight.

Researchers point to several direct mechanisms: reduced systemic inflammation (including C-reactive protein associated with plaque instability), modest but consistent reductions in systolic blood pressure, improved kidney function markers, and possible direct effects on endothelial function. The semaglutide cardiovascular benefits are likely multifactorial. According to the American Heart Association’s coverage of the FDA approval, the SELECT results represented a genuine expansion in how cardiologists think about GLP-1 medications — not just as metabolic drugs, but as agents with direct cardiovascular action.

The FDA Approval That Changed the Conversation

In March 2024, the FDA approved a new indication for Wegovy (semaglutide 2.4mg, Novo Nordisk): reducing the risk of serious cardiovascular events in adults with obesity or overweight who have established cardiovascular disease. This was the first FDA approval of a weight-management medication for cardiovascular risk reduction, based directly on the SELECT trial. Per the FDA’s announcement, the indication requires BMI ≥27 plus established CVD — prior heart attack, stroke, or peripheral arterial disease. It does not apply to adults whose only concern is elevated risk factors without a prior event.

Two points deserve to be stated as clearly as possible. Semaglutide (Wegovy) is FDA-approved to reduce cardiovascular risk in adults with obesity or overweight who have established cardiovascular disease — this is the branded Wegovy product from Novo Nordisk that completed the full FDA drug approval process. Compounded semaglutide is NOT FDA-approved for any indication, including cardiovascular risk reduction. The compounded formulation contains the same active molecule but has not undergone the FDA’s safety and efficacy review. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products.

What This Means for Women Over 40 — and GLP-1 Stroke Prevention

Cardiovascular disease is the number one cause of death in US women. Women are historically under-represented in cardiovascular research and under-treated for early-stage CVD — symptoms are more likely to be atypical and attributed to non-cardiac causes. Risk accelerates after menopause when estrogen’s protective effects on lipid profiles and vascular function diminish, so a woman with a healthy lipid panel at 45 may have elevated LDL at 53 with no lifestyle change.

The SELECT trial’s GLP-1 stroke prevention and heart attack reduction findings are most directly relevant for women in their 50s who have already experienced a cardiovascular event and who have obesity or overweight — exactly the population enrolled. For them, the semaglutide cardiovascular benefits data is directly applicable, and the conversation belongs with their cardiologist. For women on a GLP-1 for weight management without established CVD, the data is useful background but not a clinical directive. Our post on the GLP-1 microdosing trend and women over 40 covers individualized approaches in practice.

What This Doesn’t Mean — The Critical Caveats

This is the section that matters most, and it deserves to be read carefully before any other part of this article is shared or acted on.

The 20% applies to a specific patient population

The SELECT trial enrolled patients with obesity or overweight who already had established cardiovascular disease and did not have diabetes. The 20% MACE reduction applies to that population. It does not directly apply to someone who has never had a heart attack or stroke. It does not apply to someone whose only cardiovascular concern is early risk factors. The translation from high-risk established CVD patients to a general population taking a GLP-1 for weight loss is not supported by the SELECT data.

Wegovy FDA approval is not a blanket endorsement of semaglutide for heart health

Brand-name Wegovy (semaglutide 2.4mg from Novo Nordisk) is FDA-approved for cardiovascular risk reduction in the defined patient population. This approval does not extend to:

• Compounded semaglutide. Compounded semaglutide is NOT FDA-approved for any indication, including cardiovascular risk reduction. The compounded formulation contains the same active molecule but has not undergone the FDA’s safety and efficacy review for this use. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products.
• Tirzepatide (the medication most SkinnyVIP patients use). Tirzepatide does NOT have FDA approval for cardiovascular risk reduction. The SURMOUNT-MMO trial is currently testing tirzepatide’s cardiovascular effects; results are expected around 2027. Tirzepatide may ultimately show similar or stronger benefits — the data will determine that, not assumption.
• All patients with obesity. The approval requires established cardiovascular disease. Adults with obesity who do not have a prior heart attack, stroke, or peripheral arterial disease are not in the approved population for this specific indication.

A GLP-1 is not a replacement for cardiovascular medications

The SELECT trial was conducted in patients who were also receiving standard-of-care cardiovascular medications: statins, ACE inhibitors, beta-blockers, and antiplatelet therapy. The 20% additional risk reduction was on top of those medications, not in place of them. A GLP-1 does not replace a statin. It does not replace an ACE inhibitor. It does not replace aspirin therapy where indicated. Any patient adding semaglutide for cardiovascular reasons should be doing so in collaboration with the physician managing their cardiovascular care — not as a self-directed substitute for existing therapy.

This is not a reason to start a GLP-1 primarily to prevent heart disease

The SELECT trial enrolled patients already taking semaglutide in a carefully monitored clinical setting with comprehensive cardiovascular care. Using this data as a reason to independently seek a GLP-1 prescription for heart disease prevention — outside of an appropriate medical evaluation — is not how the evidence should be applied. The starting point is always a physician who can evaluate your cardiovascular risk profile, your current medications, and whether an FDA-approved indication applies to your situation.

How This Connects to Other GLP-1 Benefits

The SELECT trial doesn’t sit in isolation. Reduced systemic inflammation, improved endothelial function, and better metabolic signaling drive effects across multiple systems — not just cardiovascular. The reward pathway changes documented in GLP-1 and alcohol craving research involve some of the same anti-inflammatory mechanisms contributing to cardiovascular benefit. The microdosing approach many women over 40 are using reflects clinical recognition that dose optimization for individual response matters. The broader financial behavioral picture is documented in the Walmart GLP-1 spending analysis. The cardiovascular data is the most formally validated part of a larger pattern. That the SELECT trial and the Wegovy FDA approval exist is what it looks like when evidence reaches the bar for regulatory recognition — most of the other GLP-1 benefits in this series haven’t cleared that bar yet.

The Physician’s Perspective

In the words of Dr. SkinnyVIP: “When patients ask whether their GLP-1 is helping their heart, my answer depends on what we’re treating. If you’re on a GLP-1 for weight management and you have obesity plus established cardiovascular disease, the SELECT trial suggests you may be getting an additional benefit on top of your cardiovascular medications. But I don’t prescribe GLP-1s to prevent heart disease — I prescribe them for FDA-approved indications, with appropriate cardiovascular risk assessment. And compounded semaglutide is NOT FDA-approved for cardiovascular risk reduction or for any indication — that distinction matters both for regulatory integrity and for honest patient conversations about what their medication is and isn’t approved to do.”

The Bottom Line

Three things are true about the SELECT trial results and their implications, and all three need to be held together.

First: The SELECT trial showed a real, clinically meaningful 20% reduction in major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, and non-fatal stroke — in patients with obesity or overweight and established cardiovascular disease who were treated with semaglutide over three-plus years. This was a large, rigorous, randomized, placebo-controlled trial published in the New England Journal of Medicine. The finding is solid.

Second: The FDA cardiovascular approval is for branded Wegovy (semaglutide 2.4mg from Novo Nordisk) in adults with obesity or overweight who have established cardiovascular disease. That approval is not for compounded semaglutide — which is NOT FDA-approved for any indication including this one. It is not for tirzepatide, which does not yet have cardiovascular outcome trial data supporting an FDA cardiovascular indication. And it is not for all adults with obesity, only those with established CVD.

Third: For most SkinnyVIP patients who are on compounded medications for weight management and do not have established cardiovascular disease, the cardiovascular conversation is one for their physician — not for a weight loss program. The SELECT data is important background information. It is not a clinical recommendation for any individual patient. If you have established cardiovascular disease, the most important next step is discussing your full medication regimen and treatment goals with the physician managing your heart health.

Disclaimer: This content is for informational purposes only and is not medical advice. Results vary. Semaglutide (Wegovy) is FDA-approved to reduce cardiovascular risk only in adults with obesity or overweight who have established cardiovascular disease — based on the March 2024 FDA approval. Compounded semaglutide is NOT FDA-approved for any indication, including cardiovascular risk reduction. Tirzepatide does NOT have FDA approval for cardiovascular risk reduction. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products. Always consult with a licensed physician before starting or changing any medication, and discuss cardiovascular risk management with the physician overseeing your heart health.